About Variational AI
Variational AI is a generative AI drug discovery company founded in 2019 and headquartered in Vancouver, Canada. The company has developed Enki™, a foundation model platform purpose-built for the earliest stages of small molecule drug discovery. Enki™ generates novel, synthesizable small molecules optimized across multiple parameters including potency, selectivity, ADMET properties, and synthetic feasibility. The platform is pre-trained on 760+ drug targets spanning kinases, GPCRs, proteases, oxidoreductases, hydrolases, ion channels, and other key target classes. By using generative AI to design compounds de novo rather than screening existing libraries, Variational AI enables pharmaceutical and biotech partners to explore uncharted regions of chemical space and discover first- and best-in-class compounds. The company's mission is to redefine the unit economics of drug discovery, enabling partners to bring novel therapeutics to patients faster and more cost-effectively. Enki™ simultaneously optimizes across 50+ parameters and can perform hyper-efficient lead optimization while constrained to defined scaffolds. The platform eliminates traditional hit identification and hit-to-lead phases, allowing R&D teams to move directly into lead optimization with higher-quality starting points. Variational AI's multidisciplinary team combines expertise in machine learning, medicinal chemistry, and computational chemistry, with AI scientists trained at institutions including MIT, Caltech, Berkeley, Google, Microsoft Research, and D-Wave Quantum. The company collaborates with pharmaceutical companies including Merck, and works across therapeutic areas from oncology to chronic inflammatory conditions.
Mission & Story
Mission
To redefine the unit economics of drug discovery, enabling biopharma partners to bring novel therapeutics to patients faster and more cost-effectively
Founding Story
Founded in 2019 by Handol Kim (CEO), Jason Rolfe PhD (CTO), and Ali Saberali PhD (Head of Platform). The founding team brings together expertise from leading academic and industrial laboratories including MIT, Caltech, Berkeley, Google, Microsoft Research, and D-Wave Quantum.
Clinical Focus
Medical conditions and clinical areas addressed by Variational AI.
Who It Serves
Milestones & Awards
Recent Milestones
Enki 4 platform release (April 2026) with expanded target coverage to 760 targets and applicability to proximity-based therapeutics. Collaboration with Merck announced (September 2025). $5.5M oversubscribed financing (February 2025). Named Emerging Company of the Year - Biotech by Life Sciences BC (July 2025). Multiple new partnerships in 2025-2026 including 3C Therapeutics, Rakovina Therapeutics expansion, and Oncocross collaboration.
Awards & Recognition
Emerging Company of the Year – Biotech by Life Sciences BC (2025)
Key Partnerships
Social & Media
Follow on
Latest Updates
Variational AI at WebSummit Vancouver 2026
Variational AI featured in AWS’s “Canada’s AI Innovators” series
3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Variational AI at the BC Tech Annual Member Summit
Variational AI to Participate in the Bloom Burton Healthcare Investor Conference
Company Details
- Founded
- 2019
- Headquarters
- Vancouver, BC, Canada
- Employees
- 11-50
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.